Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $368.36 | $7.29 | 4,952.60% | 7,367.20x | 354.16x | 8.16x | 9.88x | 19.70x | $529.27M | 1.30% | $4.13B | 37.48 | $38.67B | 121.60 | ||
| CORT | CORCEPT THERAPEUTICS INC | $75.75 | $32.74 | 131.37% | 75.75x | 74.45x | 10.58x | 12.61x | 1.05x | $162.57M | 2.07% | $631.90M | 6.10 | $7.85B | 118.97 | ||
| NVO | NOVO NORDISK A S | $49.16 | $151.69 | -67.59% | 13.67x | 2.05x | 4.49x | 8.34x | 0.14x | $9.34B | 4.28% | $26.18B | 5.89 | $229.09B | 9.23 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $453.97 | $29.07 | 1,461.81% | 1,464.42x | 311.81x | 18.59x | 256.42x | 6.23x | $221.36M | 0.37% | $233.89M | 1.78 | $61.70B | 406.11 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $2.22 | $5.21 | -57.40% | 27.75x | 16.91x | 2.82x | 3.55x | 0.18x | -$3.44M | -1.98% | $49.90M | 0.63 | $164.46M | 15.59 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $9.23 | $11.33 | -18.53% | 19.23x | 7.52x | 6.12x | 3.90x | 0.41x | -$23.64M | -4.58% | $133.17M | 2.38 | $527.90M | 7.85 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $40.29 | $15.16 | 165.84% | 82.22x | 38.07x | 5.03x | 5.70x | 1.23x | $101.73M | 3.38% | $535.38M | 7.17 | $2.89B | 53.92 | ||
| ARGX | ARGENX SE | $891.73 | $258.61 | 244.81% | 35.63x | 53.29x | 28,765.48x | 7.59x | 2.98x | $467.72M | 0.86% | $7.17B | 117.50 | $52.02B | 64.12 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $201.27 | $61.67 | 226.38% | 87.13x | 28.74x | 15.69x | 4.17x | 1.57x | $30.76M | 0.78% | $950.17M | 48.53 | $4.27B | 41.48 | ||
| GMAB | GENMAB A | $30.24 | $114.88 | -73.68% | 12.91x | 1.74x | 5.45x | 3.38x | 0.11x | $1.19B | 6.15% | $5.75B | 8.96 | $17.80B | 8.89 | ||
| VCEL | VERICEL CORP | $39.84 | $7.30 | 445.81% | 153.23x | 177.54x | 7.78x | 6.26x | 2.58x | $20.38M | 1.01% | $321.86M | 6.38 | $2.01B | 68.66 | ||
| KRYS | KRYSTAL BIOTECH INC | $201.21 | $84.30 | 138.69% | 29.16x | 39.50x | 15.61x | 5.13x | 1.72x | $166.02M | 2.85% | $1.14B | 39.30 | $5.45B | 28.20 | ||
| RPRX | ROYALTY PHARMA PLC | $39.73 | $41.82 | -4.99% | 22.57x | 8.67x | 7.30x | 2.38x | 0.47x | $2.11B | 12.31% | $9.62B | 22.28 | $30.94B | 29.63 | ||
| TECH | BIO-TECHNE CORP | $60.75 | $16.31 | 272.46% | 121.50x | 29.73x | 7.76x | 4.82x | 1.70x | $224.06M | 2.37% | $1.97B | 12.65 | $9.72B | 43.98 | ||
| CRMD | CORMEDIX INC | $11.21 | $16.68 | -32.78% | 4.94x | 5.29x | 3.97x | 2.36x | 1.25x | $74.42M | 8.74% | $374.13M | 4.93 | $983.65M | 8.76 | ||
| HALO | HALOZYME THERAPEUTICS INC | $71.19 | $77.16 | -7.74% | 14.56x | 11.34x | 6.71x | 16.61x | 0.55x | $602.40M | 7.22% | $503.92M | 4.30 | $9.46B | 11.19 | ||
| MDXG | MIMEDX GROUP INC | $7.47 | $3.63 | 105.98% | 26.68x | 17.23x | 2.81x | 4.63x | 1.41x | $66.82M | 6.04% | $238.95M | 1.61 | $982.45M | 14.20 | ||
| GYRE | GYRE THERAPEUTICS INC | $8.08 | $0.86 | 843.18% | 115.43x | 76.66x | 6.84x | 7.64x | 6.78x | $3.05M | 0.42% | $101.92M | 1.12 | $739.13M | 55.87 | ||
| VCYT | VERACYTE INC | $39.87 | $8.93 | 346.64% | 102.23x | 99.80x | 6.34x | 2.51x | 2.25x | $98.21M | 3.13% | $1.26B | 15.98 | $2.87B | 50.44 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $54.22 | $42.09 | 28.81% | 19.93x | 17.85x | 3.37x | 1.72x | 0.78x | $832.13M | 7.99% | $6.06B | 31.54 | $9.76B | 12.63 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $34.29 | $39.81 | -13.86% | 10.62x | 10.50x | 2.39x | 2.36x | 0.62x | $296.89M | 15.05% | $835.12M | 14.51 | $1.50B | 5.55 | ||
| INCY | INCYTE CORP | $105.41 | $67.20 | 56.86% | 17.45x | 15.13x | 4.29x | 4.45x | 1.24x | $1.20B | 5.80% | $4.65B | 23.77 | $18.27B | 10.86 | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $15.22 | $7.16 | 112.51% | 26.24x | 23.02x | 7.55x | 5.49x | 1.51x | $119.87M | 5.97% | $365.77M | 2.78 | $2.01B | 19.43 | ||
| EXEL | EXELIXIS INC | $42.35 | $27.35 | 54.84% | 17.22x | 17.67x | 4.97x | 5.26x | 1.23x | $779.77M | 6.86% | $2.16B | 8.05 | $11.15B | 12.03 | ||
| ADMA | ADMA BIOLOGICS INC | $15.70 | $9.33 | 68.33% | 17.84x | 25.94x | 7.67x | 8.67x | 1.41x | $40.73M | 1.09% | $431.19M | 1.81 | $3.75B | 21.78 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $434.52 | $173.54 | 150.38% | 30.36x | 23.64x | 9.47x | 6.37x | 1.81x | $3.34B | 3.00% | $17.32B | 67.76 | $107.14B | 22.98 | ||
| INVA | INNOVIVA INC | $22.20 | $18.26 | 21.56% | 11.75x | 18.66x | 3.95x | 1.64x | 1.16x | $196.54M | 12.82% | $1.01B | 14.63 | $1.44B | 6.71 | ||
| UTHR | UNITED THERAPEUTICS CORP | $462.30 | $194.65 | 137.50% | 16.23x | 16.46x | 6.47x | 3.02x | 6.27x | $1.12B | 5.54% | $6.59B | 150.46 | $18.56B | 10.47 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $23.02 | $10.90 | 111.23% | 12.86x | 15.48x | 4.88x | 3.07x | 21.71x | $234.54M | 8.31% | $920.25M | 7.51 | $2.14B | 6.61 | ||
| MNKD | MANNKIND CORP | $5.07 | $1.28 | 295.64% | 50.70x | 53.54x | 4.96x | -34.94x | 2.73x | $43.39M | 2.78% | -$44.55M | -0.15 | $1.79B | 24.45 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $694.99 | $351.04 | 97.98% | 16.00x | 16.25x | 5.05x | 2.36x | 2.70x | $4.22B | 5.86% | $30.96B | 298.82 | $73.24B | 12.82 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.